Acasti Pharma Inc (ACST) 0.94 $ACST
Dyslipidemia - Pipeline Review, H1 2014: 43 Company and 69 Drug Profiles
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2x75xp/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acasti Pharma Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - Biocon Limited - Biospherics.net Incorporated - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics SA - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Dezima Pharma B.V. - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Esperion Therapeutics, Inc. - Essentialis, Inc. - Euroscreen S.A. - GW Pharmaceuticals plc - Genfit SA - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - High Point Pharmaceuticals, LLC - Jenrin Discovery, Inc. - Johnson & Johnson - Kadmon Pharmaceuticals, LLC - Kareus Therapeutics, SA - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. Drug Profiles: - anacetrapib - K-877 - Nicotinic Acid - (rosuvastatin calcium ezetimibe) - Centatin - DEZ-001 - GFT-505 - DRL-17822 - K-877 - ZYH-7 - 1-Methylnicotinamide - ETC-1002 - diazoxide CR - evacetrapib - (niacin aspirin) - GWP-42003 - KD-026 - S-556971 - GWP-42004 - MGL-3196 - ARI-3037-MO - ZYT-1 - HPP-593 - NC-2400 - TAP-311 - S-556971 - DS-1442 - K-312 - SPX-8522876 For more information visit http://www.researchandmarkets.com/research/2x...slipidemia
Acasti to Present at Two Scientific Forums
GlobeNewswire - Thu May 01, 7:30AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today that it will be presenting at two upcoming scientific forums. The presentations will be on Acasti's Phase II Open Label (COLT) trial results, previously announced in August 2013. The conferences include:
Global Omega-3 Polyunsaturated Fatty Acids (PUFAs) Market Overview 2014-2020
M2 - Wed Apr 30, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k99bvz/omega3) has announced the addition of the "Global Omega-3 Polyunsaturated Fatty Acids (PUFAs) Market Overview 2014-2020" report to their offering. Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020. This 410 page global market report includes 126 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global omega-3 ingredients market volume in metric tons and value in US$ by geographic region, the product segment and application area. This study profiles 42 key global players and 106 major players across North America - 29; Europe - 35; Asia-Pacific - 30 and Rest of World - 12. The report also provides the listing of the companies engaged in the manufacturing and supply of omega-3 PUFAs as well as major players in the omega-3 end-use industries such as human nutrition, pet nutrition and pharmaceuticals and major ingredient distributors across the globe. The global list of companies covers addresses, contact numbers and the website addresses of 294 companies. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. GLOBAL REGULATORY LANDSCAPE FOR OMEGA-3 FATTY ACIDS 3. KEY MARKET TRENDS 4. INDUSTRY STRUCTURE AND COMPETETIVE LANDSCAPE 5. KEY GLOBAL PLAYERS 6. KEY BUSINESS TRENDS 7. KEY PRODUCT/TECHNOLOGY TRENDS 8. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: OMEGA-3 PATENT LANDSCAPE PART
GUIDE TO THE INDUSTRY PART E: ANNEXURE Companies Mentioned - Aker Biomarine AS - Algae Biosciences Corporation - Aurora Algae, Inc. - Austral Group S.A.A. - Ayanda AS - BASF SE - Enzymotec Ltd. - EPAX AS - Felda IFFCO LLC - GC Rieber Oils - Golden Omega SA - Guangdong Runke Bioengineering Co Ltd - Huatai Biopharm Inc. - LYSI hf. - Marine Ingredients - Maruha Nichiro Foods Inc. - Neptune Technologies & Bioressources Inc. - Acasti Pharma Inc. - Nippon Suisan Kaisha, Ltd. (Nissui) - Olvea Fish Oils (Olvea Group) - Omega Protein Corp. - Polaris Nutritional Lipids - Qualitas Health Inc - Royal DSM NV - Seven Seas Ltd - Sinomega Biotech Engineering Co Ltd - Smit Functional Oils (Smit & Zoon Group) - Solutex GC, S.L. - Source-Omega LLC - Stepan Company For more information visit http://www.researchandmarkets.com/research/k99bvz/omega3
Neptune, Acasti and NeuroBioPharm reports departure of CEO Henri Harland
M2 - Tue Apr 29, 3:50AM CDT
Biotechnology company Neptune Technologies & Bioressources (NasdaqCM:NEPT) (TSX:NTB.TO), Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) and NeuroBioPharm jointly disclosed on Monday the immediate resignation of its president and chief executive officer, Henri Harland.
Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO) and NeuroBioPharm Inc. ("NeuroBio" today jointly announce the resignation of Henri Harland as President and Chief Executive Officer of Neptune, Acasti and NeuroBio with immediate effect. Mr. Harland remains a Director of Neptune, Acasti and NeuroBio.
Neptune and Enzymotec Conclude Final Patent Infringement Settlement ad License Agreement
GlobeNewswire - Sun Apr 27, 7:33PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that resolves the International Trade Commission's ("ITC" investigation of infringement of Neptune's composition of matter patents, related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review proceedings requested by Enzymotec.
Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware.
4 Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 18, 8:41PM CDT
These under-$10 stocks are within range of triggering breakout trades.
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Omega-3 Polyunsaturated Fatty Acids (PUFAs) - 2014 Global Market Overview
M2 - Tue Feb 25, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/mb5wq7/omega3) has announced the addition of the "Omega-3 Polyunsaturated Fatty Acids (PUFAs) - A Global Market Overview" report to their offering. Pharmaceutical drugs, by default, have started incorporating higher concentrations of omega-3 and it is anticipated that, over the coming few years, several new companies would be jumping on to the bandwagon of omega-3 drugs. Several drugs are in Phase II or Phase III clinical trials, with several more expected to come on-stream quite soon. However, the coming year or two is likely to witness an influx of new companies invading the global omega-3 market, provided they obtain the USFDA's or other relevant authorities' approvals. In a global scenario where increasing attention is being directed towards issues of sustainability and limited food supplies, algal sources offer immense scope for the rapidly expanding omega-3 market to continue in the same vein. The focus on obtaining EPA and DHA from algae was prompted by an endeavor to seek out more sustainable sources, since EPA and DHA are naturally contained in algae. Moreover, the omega-3 content in fish and krill originates from their consuming the algae directly or other creatures that feed on algae. In addition to being sustainable, algae also allows for farming that can be of help in putting up desirable labels, such as vegetarian, kosher or even organic. The past several decades have been witness to research studies that have underscored the significance of omega-3 fatty acids in maintaining heart health, in addition to safeguarding against cancer and birth defects and offsetting symptoms of diabetes, arthritis, cognitive decline, depression and several other conditions. Omega-3 Polyunsaturated Fatty Acids (PUFAs) have been growing and continues to grow significantly in the future, attributed to the above benefits. The report reviews, analyses and projects the market of marine and algal omega-3 polyunsaturated fatty acid ingredients for global and the regional markets including North America, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 13 independent countries. Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020. Key Topics Covered Part A: Global Market Perspective 1. Introduction 2. Global Regulatory Landscape For Omega-3 Fatty Acids 3. Key Market Trends 4. Industry Structure And Competetive Landscape 5. Key Global Players 6. Key Business Trends 7. Key Product/Technology Trends 8. Global Market Overview Part B: Regional Market Perspective 1. Global Omega-3 Pufas Market Overview By Geographic Region 2. Global Marine Omega-3 Pufas Market Overview By Geographic Region 3. Global Algal Omega-3 Pufas Market Overview By Geographic Region 4. Global Omega-3 Pufas End-Use Application Market Overview By Geographic Region Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Omega-3 Patent Landscape 1. Fish Oil Omega-3 Fatty Acids 2. Algal Oil Omega-3 Fatty Acids Part Guide To The Industry 1. Manufacturers Of Omega 3 Ingredients 2. Pharma Companies In Omega 3 Drugs Market 3. Raw Material Producers, Omega 3 End Users And Other Related Companies In Omega 3 Industry 4. Major Ingredient Distributors Part E: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned Examples of companies mentioned include: - Acasti Pharma - Aker Biomarine - Algae Biosciences - Aurora Algae - Ayanda - BASF - Chemport - Croda International - GC Rieber Oils - Golden Omega - Hubei Fuxing Biotechnology - Jiangsu Auqi Marine Biotechnology - Marine Ingredients - Maruha Nichiro Foods - Neptune Technologies & Bioressources - Nippon Suisan Kaisha(Nissui) - Olvea Fish Oils (Olvea Group) - Omega Protein - Pharma Marine - Polaris Nutritional Lipids - Qualitas Health - Sinomega Biotech Engineering - Smit Functional Oils (Smit & Zoon Group) - Solutex GC - Source-Omega - Stepan - TASA Omega (Tecnol?gica De Alimentos) - Zhejiang Shenzhou Marine Bio-Tech ... and more For more information visit http://www.researchandmarkets.com/research/mb5wq7/omega3 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
TSX Venture Exchange Daily Bulletins
CNW Group - Fri Feb 21, 5:26PM CST
TSX VENTURE COMPANIES:
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti Pharma Inc concludes CAD2.15m private placement
M2 - Mon Feb 10, 6:33AM CST
Biopharmaceutical company Acasti Pharma Inc (NasdaqCM:ACST) (TSX:APO.V) reported on Friday the completion of a private placement of CAD2,150,000 units at CAD1.33 per unit.
Acasti Announces Closing of CAD$2.15 Million Private Placement
GlobeNewswire - Fri Feb 07, 7:00AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today the closing of a private placement of CAD$2,150,000 of units of Acasti ("Units" at a price of CAD$1.33 per Unit, each Unit consisting of one (1) Class A share ("Common Share" and one (1) Common Share purchase warrant ("Warrant" of Acasti (the "Private Placement" . Each Warrant will entitle the holder to purchase one Common Share ("Warrant Share" at an exercise price of CAD$1.60 per Warrant Share, subject to adjustment, at any time until 5:00 p.m. (Montreal time) on December 3, 2018.
5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 06, 2:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 14, 6:29AM CST
Acasti Pharma ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc.'s ("Neptune" subsidiary, announces its financial results for the three and nine-month periods ended November 30, 2013.
FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial
GlobeNewswire - Thu Jan 09, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company, announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) submission to initiate a Pharmacokinetic (PK) trial of CaPrein the U.S., having found no objections with the PK trial design, protocol, or safety profile of CaPre. Following the clearance, Acasti engaged Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, to conduct its PK study.
Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently.
Neptune, Acasti and Enzymotec Sign Settlement Term Sheet Resulting in Stay of ITC Investigation for 30 Days
GlobeNewswire - Wed Dec 18, 7:59AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that on December 16, 2013, the Administrative Law Judge presiding over the pending International Trade Commission (ITC) Investigation involving Neptune and Acasti; and Enzymotec Ltd., and Enzymotec USA, Inc. (collectively, "Enzymotec" granted the parties' joint motion to stay the proceedings for thirty days. The investigation was instituted earlier this year by Neptune and Acasti in a complaint filed with the ITC alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players.
Dyslipidemia - Pipeline Review, H1 2014: 43 Company and 69 Drug Profiles
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2x75xp/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acasti Pharma Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - Biocon Limited - Biospherics.net Incorporated - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics SA - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Dezima Pharma B.V. - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Esperion Therapeutics, Inc. - Essentialis, Inc. - Euroscreen S.A. - GW Pharmaceuticals plc - Genfit SA - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - High Point Pharmaceuticals, LLC - Jenrin Discovery, Inc. - Johnson & Johnson - Kadmon Pharmaceuticals, LLC - Kareus Therapeutics, SA - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. Drug Profiles: - anacetrapib - K-877 - Nicotinic Acid - (rosuvastatin calcium ezetimibe) - Centatin - DEZ-001 - GFT-505 - DRL-17822 - K-877 - ZYH-7 - 1-Methylnicotinamide - ETC-1002 - diazoxide CR - evacetrapib - (niacin aspirin) - GWP-42003 - KD-026 - S-556971 - GWP-42004 - MGL-3196 - ARI-3037-MO - ZYT-1 - HPP-593 - NC-2400 - TAP-311 - S-556971 - DS-1442 - K-312 - SPX-8522876 For more information visit http://www.researchandmarkets.com/research/2x...slipidemia
Acasti to Present at Two Scientific Forums
GlobeNewswire - Thu May 01, 7:30AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today that it will be presenting at two upcoming scientific forums. The presentations will be on Acasti's Phase II Open Label (COLT) trial results, previously announced in August 2013. The conferences include: Global Omega-3 Polyunsaturated Fatty Acids (PUFAs) Market Overview 2014-2020
M2 - Wed Apr 30, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k99bvz/omega3) has announced the addition of the "Global Omega-3 Polyunsaturated Fatty Acids (PUFAs) Market Overview 2014-2020" report to their offering. Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020. This 410 page global market report includes 126 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global omega-3 ingredients market volume in metric tons and value in US$ by geographic region, the product segment and application area. This study profiles 42 key global players and 106 major players across North America - 29; Europe - 35; Asia-Pacific - 30 and Rest of World - 12. The report also provides the listing of the companies engaged in the manufacturing and supply of omega-3 PUFAs as well as major players in the omega-3 end-use industries such as human nutrition, pet nutrition and pharmaceuticals and major ingredient distributors across the globe. The global list of companies covers addresses, contact numbers and the website addresses of 294 companies. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. GLOBAL REGULATORY LANDSCAPE FOR OMEGA-3 FATTY ACIDS 3. KEY MARKET TRENDS 4. INDUSTRY STRUCTURE AND COMPETETIVE LANDSCAPE 5. KEY GLOBAL PLAYERS 6. KEY BUSINESS TRENDS 7. KEY PRODUCT/TECHNOLOGY TRENDS 8. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE REGIONAL MARKET OVERVIEW 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: OMEGA-3 PATENT LANDSCAPE PART
GUIDE TO THE INDUSTRY PART E: ANNEXURE Companies Mentioned - Aker Biomarine AS - Algae Biosciences Corporation - Aurora Algae, Inc. - Austral Group S.A.A. - Ayanda AS - BASF SE - Enzymotec Ltd. - EPAX AS - Felda IFFCO LLC - GC Rieber Oils - Golden Omega SA - Guangdong Runke Bioengineering Co Ltd - Huatai Biopharm Inc. - LYSI hf. - Marine Ingredients - Maruha Nichiro Foods Inc. - Neptune Technologies & Bioressources Inc. - Acasti Pharma Inc. - Nippon Suisan Kaisha, Ltd. (Nissui) - Olvea Fish Oils (Olvea Group) - Omega Protein Corp. - Polaris Nutritional Lipids - Qualitas Health Inc - Royal DSM NV - Seven Seas Ltd - Sinomega Biotech Engineering Co Ltd - Smit Functional Oils (Smit & Zoon Group) - Solutex GC, S.L. - Source-Omega LLC - Stepan Company For more information visit http://www.researchandmarkets.com/research/k99bvz/omega3 Neptune, Acasti and NeuroBioPharm reports departure of CEO Henri Harland
M2 - Tue Apr 29, 3:50AM CDT
Biotechnology company Neptune Technologies & Bioressources (NasdaqCM:NEPT) (TSX:NTB.TO), Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) and NeuroBioPharm jointly disclosed on Monday the immediate resignation of its president and chief executive officer, Henri Harland.
Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO) and NeuroBioPharm Inc. ("NeuroBio" today jointly announce the resignation of Henri Harland as President and Chief Executive Officer of Neptune, Acasti and NeuroBio with immediate effect. Mr. Harland remains a Director of Neptune, Acasti and NeuroBio. Neptune and Enzymotec Conclude Final Patent Infringement Settlement ad License Agreement
GlobeNewswire - Sun Apr 27, 7:33PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that resolves the International Trade Commission's ("ITC" investigation of infringement of Neptune's composition of matter patents, related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review proceedings requested by Enzymotec. Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware. 4 Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 18, 8:41PM CDT
These under-$10 stocks are within range of triggering breakout trades.
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Omega-3 Polyunsaturated Fatty Acids (PUFAs) - 2014 Global Market Overview
M2 - Tue Feb 25, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/mb5wq7/omega3) has announced the addition of the "Omega-3 Polyunsaturated Fatty Acids (PUFAs) - A Global Market Overview" report to their offering. Pharmaceutical drugs, by default, have started incorporating higher concentrations of omega-3 and it is anticipated that, over the coming few years, several new companies would be jumping on to the bandwagon of omega-3 drugs. Several drugs are in Phase II or Phase III clinical trials, with several more expected to come on-stream quite soon. However, the coming year or two is likely to witness an influx of new companies invading the global omega-3 market, provided they obtain the USFDA's or other relevant authorities' approvals. In a global scenario where increasing attention is being directed towards issues of sustainability and limited food supplies, algal sources offer immense scope for the rapidly expanding omega-3 market to continue in the same vein. The focus on obtaining EPA and DHA from algae was prompted by an endeavor to seek out more sustainable sources, since EPA and DHA are naturally contained in algae. Moreover, the omega-3 content in fish and krill originates from their consuming the algae directly or other creatures that feed on algae. In addition to being sustainable, algae also allows for farming that can be of help in putting up desirable labels, such as vegetarian, kosher or even organic. The past several decades have been witness to research studies that have underscored the significance of omega-3 fatty acids in maintaining heart health, in addition to safeguarding against cancer and birth defects and offsetting symptoms of diabetes, arthritis, cognitive decline, depression and several other conditions. Omega-3 Polyunsaturated Fatty Acids (PUFAs) have been growing and continues to grow significantly in the future, attributed to the above benefits. The report reviews, analyses and projects the market of marine and algal omega-3 polyunsaturated fatty acid ingredients for global and the regional markets including North America, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 13 independent countries. Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020. Key Topics Covered Part A: Global Market Perspective 1. Introduction 2. Global Regulatory Landscape For Omega-3 Fatty Acids 3. Key Market Trends 4. Industry Structure And Competetive Landscape 5. Key Global Players 6. Key Business Trends 7. Key Product/Technology Trends 8. Global Market Overview Part B: Regional Market Perspective 1. Global Omega-3 Pufas Market Overview By Geographic Region 2. Global Marine Omega-3 Pufas Market Overview By Geographic Region 3. Global Algal Omega-3 Pufas Market Overview By Geographic Region 4. Global Omega-3 Pufas End-Use Application Market Overview By Geographic Region Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Omega-3 Patent Landscape 1. Fish Oil Omega-3 Fatty Acids 2. Algal Oil Omega-3 Fatty Acids Part
Guide To The Industry 1. Manufacturers Of Omega 3 Ingredients 2. Pharma Companies In Omega 3 Drugs Market 3. Raw Material Producers, Omega 3 End Users And Other Related Companies In Omega 3 Industry 4. Major Ingredient Distributors Part E: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned Examples of companies mentioned include: - Acasti Pharma - Aker Biomarine - Algae Biosciences - Aurora Algae - Ayanda - BASF - Chemport - Croda International - GC Rieber Oils - Golden Omega - Hubei Fuxing Biotechnology - Jiangsu Auqi Marine Biotechnology - Marine Ingredients - Maruha Nichiro Foods - Neptune Technologies & Bioressources - Nippon Suisan Kaisha(Nissui) - Olvea Fish Oils (Olvea Group) - Omega Protein - Pharma Marine - Polaris Nutritional Lipids - Qualitas Health - Sinomega Biotech Engineering - Smit Functional Oils (Smit & Zoon Group) - Solutex GC - Source-Omega - Stepan - TASA Omega (Tecnol?gica De Alimentos) - Zhejiang Shenzhou Marine Bio-Tech ... and more For more information visit http://www.researchandmarkets.com/research/mb5wq7/omega3 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products. TSX Venture Exchange Daily Bulletins
CNW Group - Fri Feb 21, 5:26PM CST
TSX VENTURE COMPANIES:
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding. Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding. Acasti Pharma Inc concludes CAD2.15m private placement
M2 - Mon Feb 10, 6:33AM CST
Biopharmaceutical company Acasti Pharma Inc (NasdaqCM:ACST) (TSX:APO.V) reported on Friday the completion of a private placement of CAD2,150,000 units at CAD1.33 per unit.
Acasti Announces Closing of CAD$2.15 Million Private Placement
GlobeNewswire - Fri Feb 07, 7:00AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today the closing of a private placement of CAD$2,150,000 of units of Acasti ("Units" at a price of CAD$1.33 per Unit, each Unit consisting of one (1) Class A share ("Common Share" and one (1) Common Share purchase warrant ("Warrant" of Acasti (the "Private Placement" . Each Warrant will entitle the holder to purchase one Common Share ("Warrant Share" at an exercise price of CAD$1.60 per Warrant Share, subject to adjustment, at any time until 5:00 p.m. (Montreal time) on December 3, 2018. 5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 06, 2:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 14, 6:29AM CST
Acasti Pharma ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc.'s ("Neptune" subsidiary, announces its financial results for the three and nine-month periods ended November 30, 2013. FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial
GlobeNewswire - Thu Jan 09, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company, announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) submission to initiate a Pharmacokinetic (PK) trial of CaPrein the U.S., having found no objections with the PK trial design, protocol, or safety profile of CaPre. Following the clearance, Acasti engaged Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, to conduct its PK study. Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Thu Dec 19, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the appointment of Jerald J. Wenker as a special advisor to its Board of Directors. Mr. Wenker has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholder approval, including increasing the maximum number of Board of Directors to at least 7 members from 6 currently. Neptune, Acasti and Enzymotec Sign Settlement Term Sheet Resulting in Stay of ITC Investigation for 30 Days
GlobeNewswire - Wed Dec 18, 7:59AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that on December 16, 2013, the Administrative Law Judge presiding over the pending International Trade Commission (ITC) Investigation involving Neptune and Acasti; and Enzymotec Ltd., and Enzymotec USA, Inc. (collectively, "Enzymotec" granted the parties' joint motion to stay the proceedings for thirty days. The investigation was instituted earlier this year by Neptune and Acasti in a complaint filed with the ITC alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players. 
